Tandem Diabetes Care Future Growth

Future criteria checks 1/6

Tandem Diabetes Care is forecast to grow earnings and revenue by 52.5% and 10.6% per annum respectively. EPS is expected to grow by 53.5% per annum. Return on equity is forecast to be -0.8% in 3 years.

Key information

52.5%

Earnings growth rate

53.5%

EPS growth rate

Medical Equipment earnings growth	18.5%
Revenue growth rate	10.6%
Future return on equity	-0.8%
Analyst coverage	Good
Last updated	22 Sep 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BOVESPA:T2ND34 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,098	-46	N/A	N/A	14
12/31/2025	989	-80	-11	N/A	18
12/31/2024	890	-116	-19	N/A	18
6/30/2024	796	-136	-64	-20	N/A
3/31/2024	770	-141	-67	-21	N/A
12/31/2023	748	-223	-83	-32	N/A
9/30/2023	771	-208	-49	-19	N/A
6/30/2023	790	-224	-41	5	N/A
3/31/2023	795	-204	-33	18	N/A
12/31/2022	801	-95	8	50	N/A
9/30/2022	791	-68	21	64	N/A
6/30/2022	766	-13	50	74	N/A
3/31/2022	738	6	74	96	N/A
12/31/2021	703	16	88	111	N/A
9/30/2021	661	22	85	107	N/A
6/30/2021	605	7	62	87	N/A
3/31/2021	542	-25	45	74	N/A
12/31/2020	499	-34	-8	25	N/A
9/30/2020	439	-49	-6	29	N/A
6/30/2020	410	-42	5	37	N/A
3/31/2020	394	-17	1	25	N/A
12/31/2019	362	-25	22	42	N/A
9/30/2019	330	-24	23	37	N/A
6/30/2019	282	-55	0	10	N/A
3/31/2019	223	-113	-4	0	N/A
12/31/2018	184	-123	-11	-8	N/A
9/30/2018	148	-138	-38	-34	N/A
6/30/2018	129	-119	-52	-50	N/A
3/31/2018	116	-82	N/A	-58	N/A
12/31/2017	108	-73	N/A	-66	N/A
9/30/2017	96	-76	N/A	-68	N/A
6/30/2017	82	-90	N/A	-67	N/A
3/31/2017	83	-87	N/A	-66	N/A
12/31/2016	84	-83	N/A	-61	N/A
9/30/2016	84	-81	N/A	-58	N/A
6/30/2016	88	-70	N/A	-54	N/A
3/31/2016	81	-72	N/A	-59	N/A
12/31/2015	73	-72	N/A	-59	N/A
9/30/2015	62	-79	N/A	-62	N/A
6/30/2015	59	-79	N/A	-61	N/A
3/31/2015	54	-79	N/A	-60	N/A
12/31/2014	50	-80	N/A	-61	N/A
9/30/2014	42	-85	N/A	-61	N/A
6/30/2014	36	-78	N/A	-58	N/A
3/31/2014	32	-74	N/A	-56	N/A
12/31/2013	29	-63	N/A	-48	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: T2ND34 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: T2ND34 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: T2ND34 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: T2ND34's revenue (10.6% per year) is forecast to grow faster than the BR market (7.9% per year).

High Growth Revenue: T2ND34's revenue (10.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: T2ND34 is forecast to be unprofitable in 3 years.

Tandem Diabetes Care Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Tandem Diabetes Care, Inc. Updates Sales Guidance for the Full Year of 2022

Tandem Diabetes Care, Inc. Revises Financial Guidance for the Full Year Ending December 31, 2022

Recent updates

Tandem Diabetes Care to Release Updated iOS t:connect Mobile App for t:slim X2 Insulin Pump Users Impacted by March 2024 Nationwide Recall

Tandem Diabetes Care, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Tandem Diabetes Care, Inc.(NasdaqGM:TNDM) dropped from Russell 3000E Value Index

Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024

Tandem Diabetes Care, Inc. to Report Q1, 2024 Results on May 02, 2024

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Tandem Diabetes Care, Inc. to Report Q4, 2023 Results on Feb 21, 2024

Tandem Diabetes Care, Inc. Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers

Tandem Diabetes Care, Inc. Launches T:Slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S

Tandem Diabetes Care, Inc. Appoints Mark Novara as Executive Vice President and Chief Commercial Officer, Effective November 13, 2023

Tandem Diabetes Care, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Holzer & Holzer, LLC Files Class Action Lawsuit Filed on Behalf of Tandem Diabetes Care, Inc

Tandem Diabetes Care, Inc. Announces the Resignation of Brian B. Hansen as Executive Vice President and Chief Commercial Officer, Effective December 31, 2023

Tandem Diabetes Care, Inc. Receives U.S. FDA Clearance

Tandem Diabetes Care, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) completed the acquisition of AMF Medical SA .

Tandem Diabetes Care, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million.

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million.

Tandem Diabetes Care, Inc. Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology

Tandem Diabetes Care, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Tandem Diabetes Care Achieves Milestone of 1 Million Insulin Boluses Delivered Using Its t:Connect Mobile App

Tandem Diabetes Care, Inc. Updates Sales Guidance for the Full Year of 2022

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) acquired Capillary Biomedical, Inc.

Tandem Diabetes Care, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Tandem Diabetes Care Reports the Appointments of Myoung Cha and Joao Malagueira as Independent Members of Its Board of Directors, as of June 15, 2022

Tandem Diabetes Care, Inc. Appoints Myoung Cha and Joao Malagueira as Independent Members of its Board of Directors

Tandem Diabetes Care, Inc. Revises Financial Guidance for the Full Year Ending December 31, 2022

Tandem Diabetes Care, Inc., Annual General Meeting, May 25, 2022

Tandem Diabetes Care, Inc. to Report Q1, 2022 Results on May 04, 2022

Tandem Diabetes Care, Inc. Appoints David B. Berger as Executive Vice President, Chief Operating Officer and Assistant Secretary

Tandem Diabetes Care, Inc. Announces FDA Clearance for the t:slim X2 Insulin Pump to Bolus Using the t:connect Mobile App

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies